

Onpattro® (patisiran) Injectable Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: 1-866-752-7021 (TTY: 711)

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B:
Please Use Medicare Request Form

	art of treatment: Start date		, , ,	··· <i>)</i> F	lease Use Med	licare Request Form		
	ontinuation of therapy: Date ted By:	· · · · · · · · · · · · · · · · · · ·			Fax:			
A. PATIENT INFORMATIO								
First Name:		Last Name:			DOB:			
Address:			City:		State:	ZIP:		
Home Phone:	Work Phone:		Cell Phone:		Email:			
Patient Current Weight:	lbs orkgs P	atient Height: ir	nches or cn	ns Allergies:				
B. INSURANCE INFORMA		<u></u>	<u> </u>					
Aetna Member ID #:	Does patient have oth	ner coverage?]Yes □ No					
Group #:		If yes, provide ID#: Carrier Name:						
	nsured: Insured:							
Medicare: Yes No	If yes, provide ID #:	M	edicaid: Yes	No If yes, p	rovide ID #:			
C. PRESCRIBER INFORM				_ , , ,				
First Name:		Last Name: (Check C		<i>One):</i> ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.				
Address:			City:		State:	ZIP:		
Phone:	Fax:	St Lic #:	NPI#:	DEA #:		UPIN:		
Provider E-mail:	<u> </u>	Office Contact Name:	:		Phone:			
Specialty (Check one):	Neurologist Other:				'			
D. DISPENSING PROVIDE	R/ADMINISTRATION INFORM	MATION						
Center Name: Home Infusion Center Agency Name: _ Administration code(s) Address:	Phone:		Name:Address:Phone:	Specialty Pharmacy Other: Name: Address: Phone: TIN: PIN:				
E. PRODUCT INFORMATION								
	(patisiran) Dose:		_ Frequency:			_		
	TION – Please indicate primary	•	•		_			
	Secor							
	ON – Required clinical informati documentation required for a		its <u>entirety</u> for all pre	certification requ	ests.			
Yes								
amyloid p ☐ Yes ☐ No Was the c ☐ Yes ☐ No Does the	patient have a diagnosis of poly olyneuropathy (ATTR-FAP))? liagnosis confirmed by detectio patient exhibit clinical manifesta n in biopsy specimens, TTR pro	neuropathy of hereditary n of a mutation of the TT ations of polyneuropathy	r transthyretin-mediate R gene? of hereditary transthy	ed amyloidosis (l	hATTR) (transth myloidosis (ATT	nyretin-type familial R-FAP) (e.g., amyloid		



Onpattro® (patisiran) Injectable Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification Phone: <u>1-866-752-7021 (TTY: 711)</u>

FAX: <u>1-888-267-3277</u>

For Medicare Advantage Part B: Please Use Medicare Request Form

Patient First Name		Patient Last Name		Patient Phone		Patient DOB				
G. CLINICAL INFORMA	ΓΙΟΝ – (continue	ed) Required clinical information mu	st be comple	ted in its <u>entirety</u> for all pre	ecertification	requests.				
Yes No Will the requested medication be used in combination with inotersen (Tegsedi), vutrisiran (Amvuttra) or tafamidis (Vyndaqel, Vyndamax)?										
Yes No Is the requested medication prescribed by or in consultation with any of the following: a) neurologist, b) geneticist, or c) physician specializing in the treatment of amyloidosis?										
Continuation Requests (clinical documentation required for all requests):										
☐ Yes ☐ No Has the patient demonstrated a beneficial response to the requested medication therapy compared to baseline (e.g., improvement of neuropathy severity and rate of disease progression as demonstrated by the modified Neuropathy Impairment Scale+7 (mNIS+7) composite score, the Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score, polyneuropathy disability (PND) score, FAP disease stage, manual grip strength)?										
H. ACKNOWLEDGEMENT										
Request Completed By (Signature Required):						Date:	1	/		
Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.										

The plan may request additional information or clarification, if needed, to evaluate requests.